MedPath

Casodex/Zoladex Hormonal therApy Study for assessMent of Correlation Between PSA & BAI in prOstate Cancer patieNts

Completed
Conditions
Prostate Cancer
Registration Number
NCT00523484
Lead Sponsor
AstraZeneca
Brief Summary

This study is an observational study to see whether anxiety level can be correlated with PSA level under the current practice in the patients of prostate cancer taking hormonal therapy. For assessment of anxiety level BAI(Beck Anxiety Inventory) will be used. The target population for this study is the patients of prostate cancer diagnosed previously and who are taking hormonal therapy with regular follow-up and PSA test. The follow-up duration will be total 6 months with interim visit at 3 month and final visit at 6 month.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
Male
Target Recruitment
1200
Inclusion Criteria
  1. Provision of written informed consent

  2. Patients who take PSA test regularly

  3. Observation suitable patients for PSA change according to hormonal treatment at least for 6months

  4. Locally advanced or advanced prostate cancer patients who is suitable for hormonal therapy

  5. Prostate Cancer Patients who has been taking one treatment among 3 hormonal therapies in below:

    • Bicalutamide Monotherapy : Bicalutamide 150mg/day
    • Goserelin 3.6mg/10.8mg
    • MAB(Maximal Androgen Blockade) :Bicalutamide 50mg + Goserelin 3.6/10.8mg
Read More
Exclusion Criteria
  1. Prohibition use under permitted indication
  2. Previous inclusion in the present study
  3. Participation in a clinical study during the last 30 days
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Research Site

🇰🇷

Seoul, Songpa-gu, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath